Skip to main content
SpringerLink
Log in

Hereditary Angioedema

  • Chapter
  • First Online:
Asthma, Allergic and Immunologic Diseases During Pregnancy

  • 594 Accesses

Abstract

Hereditary angioedema comprises a group of rare autosomal dominant disorders that manifest as recurrent attacks of swelling with attendant morbidity and mortality. HAE can occur with or without C1 inhibitor deficiency with each category comprised of additional subtypes. The underlying pathophysiology is generation of bradykinin with ensuing vascular leak and angioedema. HAE usually presents in childhood often with substantial delay until establishing the correct diagnosis, which is critically important to guide appropriate treatment. The management of HAE in women presents distinct challenges. Hormonal replacement, contraception, and pregnancy often escalate attack frequency and severity. Treatment of HAE during pregnancy provides additional complexities should the disease intensify as many of the potential therapies are not recognized as safe. This chapter reviews the current classification of HAE, impact of sex hormones, the relationship between pregnancy and severity of swelling, and the management of HAE during pregnancy and breastfeeding. Through gaining an understanding of disease mechanisms and the unique issues facing women, the clinician will be able to successfully manage HAE patients during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:586–93.

    Article  Google Scholar 

  2. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–36.

    Article  CAS  PubMed  Google Scholar 

  3. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1- esterase. Am J Med. 1963;35:37–44.

    Article  CAS  PubMed  Google Scholar 

  4. Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science. 1965;148:957–8.

    Article  CAS  PubMed  Google Scholar 

  5. Stoppa Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T. Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med. 1987;317:1–6.

    Article  CAS  PubMed  Google Scholar 

  6. Cicardi M, Igarashi T, Rosen FS, Davis AE III. Molecular basis for the deficiency of complement 1 inhibitor in type 1 hereditary angioneurotic edema. J Clin Invest. 1987;79:698–702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kramer J, Katz Y, Rosen FS, Davis AE III, Strunk RC. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest. 1991;87:1614–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davis AE 3rd, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost. 2010;104(5):886–93.

    CAS  PubMed  Google Scholar 

  9. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol. 1983;72:54–60.

    Article  CAS  PubMed  Google Scholar 

  10. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ, Curd JG, et al. Prekallikrein activation and high- molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983;308:1050–4.

    Article  CAS  PubMed  Google Scholar 

  11. Lammle B, Zuraw BL, Heeb MJ, Schwarz HP, Berrettini M, Curd JG, et al. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb Haemost. 1988;59:151–61.

    Article  CAS  PubMed  Google Scholar 

  12. Berrettini M, Lammle B, White T, Heeb MJ, Schwarz HP, Zuraw B, et al. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood. 1986;68(2):455–62.

    CAS  PubMed  Google Scholar 

  13. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351(9117):1693–7.

    Article  CAS  PubMed  Google Scholar 

  14. Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen- dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546–50.

    Article  CAS  PubMed  Google Scholar 

  15. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213–7.

    Article  CAS  PubMed  Google Scholar 

  16. Zuraw BL. Hereditary angioedema with normal C1 inhibitor: four types and counting. J Allergy Clin Immunol. 2018;141(3):884–5.

    Article  PubMed  Google Scholar 

  17. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286–9.

    Article  CAS  PubMed  Google Scholar 

  18. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet. 2006;79(6):1098–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bjorkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schonig K, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest. 2015;125(8):3132–46.

    Article  PubMed  PubMed Central  Google Scholar 

  20. de Maat S, Bjorkqvist J, Suffritti C, Wiesenekker CP, Nagtegaal W, Koekman A, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol. 2016;138(5):1414–23.

    Article  PubMed  CAS  Google Scholar 

  21. Bork K, Wulff K, Steinmuller-Magin L, Braenne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogengene. Allergy. 2018;73(2):442–50.

    Article  CAS  PubMed  Google Scholar 

  22. Bafunno V, Firinu D, D’Apolito M, Cordisco G, Loffredo S, Leccese A, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141(3):1009–17.

    Article  CAS  PubMed  Google Scholar 

  23. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003;114(4):294–8.

    Article  CAS  PubMed  Google Scholar 

  24. Baroso R, Sellier P, Defendi F, Charignon D, Ghannam A, Habib M, et al. Kininogen cleavage assay: diagnostic assistance for kinin-mediated angioedema conditions. PLoS One. 2016;11(9):e0163958.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484 e1–4.

    Article  Google Scholar 

  26. Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(Suppl 1):S145–56.

    Article  CAS  PubMed  Google Scholar 

  27. Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy. 2015;70(8):1004–12.

    Article  CAS  PubMed  Google Scholar 

  28. Zuraw BL, Davis DK, Castaldo AJ, Christiansen SC. Tolerability and effectiveness of 17-alpha-alkylated androgen therapy for hereditary angioedema: a re-examination. J Allergy Clin Immunol Pract. 2016;4(5):948–55 e15.

    Article  PubMed  Google Scholar 

  29. Tse KY, Zuraw BL, Chen Q, Christiansen SC. Anabolic androgen use in the management of hereditary angioedema: not so cheap after all. Ann Allergy Asthma Immunol. 2017;118(4):456–60.e1.

    Article  CAS  PubMed  Google Scholar 

  30. Drobnis EZ, Nangia AK. Exogenous androgens and male reproduction. Adv Exp Med Biol. 2017;1034:25–8.

    Article  PubMed  Google Scholar 

  31. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids. 2000;65(10–11):651–8.

    Article  CAS  PubMed  Google Scholar 

  32. Visy B, Fust G, Varga L, Szendei G, Takacs E, Karadi I, et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol. 2004;60(4):508–15.

    Article  CAS  Google Scholar 

  33. Saule C, Boccon-Gibod I, Fain O, Kanny G, Plu-Bureau G, Martin L, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43(4):475–82.

    Article  CAS  PubMed  Google Scholar 

  34. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346(8990):1575–82.

    Article  Google Scholar 

  35. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational research group on oral contraceptives and the health of young women. BMJ. 1996;312(7023):83–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.

    Article  Google Scholar 

  37. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.

    Article  CAS  PubMed  Google Scholar 

  38. Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood. 1985;66(3):602–5.

    CAS  PubMed  Google Scholar 

  39. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995;136(11):5076–83.

    Article  CAS  PubMed  Google Scholar 

  40. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids. 1996;61(4):270–6.

    Article  CAS  PubMed  Google Scholar 

  41. Rowan MP, Berg KA, Milam SB, Jeske NA, Roberts JL, Hargreaves KM, et al. 17beta-estradiol rapidly enhances bradykinin signaling in primary sensory neurons in vitro and in vivo. J Pharmacol Exp Ther. 2010;335(1):190–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T, et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause. 2001;8(3):210–5.

    Article  CAS  PubMed  Google Scholar 

  43. Madeddu P, Emanueli C, Song Q, Varoni MV, Demontis MP, Anania V, et al. Regulation of bradykinin B2-receptor expression by oestrogen. Br J Pharmacol. 1997;121(8):1763–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Joseph K, Tholanikunnel BG, Kaplan AP. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: implications for hereditary angioedema. J Allergy Clin Immunol. 2017;140(1):170–6.

    Article  CAS  PubMed  Google Scholar 

  45. Chen LM, Chung P, Chao S, Chao L, Chao J. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992;1131:145–51.

    Article  CAS  PubMed  Google Scholar 

  46. Madeddu P, Glorioso N, Maioli M, Demontis MP, Varoni MV, Anania V, et al. Regulation of rat renal kallikrein expression by estrogen and progesterone. J Hypertens. 1991;9:S244–S5.

    CAS  Google Scholar 

  47. Bouhnik J, Savoie F, Michaud A, Baussant T, Alhenc-Gelas F, Corvol P. Effect of sex hormones on plasma T-kininogen in the rat. Life Sci. 1989;44:1859–66.

    Article  CAS  PubMed  Google Scholar 

  48. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. N Engl J Med. 1976;295:1444–8.

    Article  CAS  PubMed  Google Scholar 

  49. Drouet C, Desormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429–33.

    Article  CAS  PubMed  Google Scholar 

  50. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308–20.

    Article  PubMed  Google Scholar 

  51. Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44–9.

    Article  CAS  PubMed  Google Scholar 

  52. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(2):131.e1–7.

    Article  CAS  Google Scholar 

  53. Satomura A, Fujita T, Nakayama T. Comparison of the frequency of angioedema attack, before and during pregnancy, in a patient with type I hereditary angioedema. Intern Med. 2018;57(5):751–5.

    Article  PubMed  Google Scholar 

  54. Chinniah N, Katelaris CH. Hereditary angioedema and pregnancy. Aust N Z J Obstet Gynaecol. 2009;49(1):2–5.

    Article  PubMed  Google Scholar 

  55. Walker JE, Campbell DM, Ogston D. Blood levels of proteinase inhibitors in pregnancy. Br J Obstet Gynaecol. 1982;89(3):208–10.

    Article  CAS  PubMed  Google Scholar 

  56. Bork K. Hereditary angioedema with normal c1 inhibitor. Immunol Allergy Clin N Am. 2013;33(4):457–70.

    Article  Google Scholar 

  57. Nielsen EW, Gran JT, Straume B, Mellbye OJ, Johansen HT, Mollnes TE. Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med. 1996;239(2):119–30.

    Article  CAS  PubMed  Google Scholar 

  58. Ebina Y, Ieko M, Naito S, Kobashi G, Deguchi M, Minakami H, et al. Low levels of plasma protein S, protein C and coagulation factor XII during early pregnancy and adverse pregnancy outcome. Thromb Haemost. 2015;114(1):65–9.

    Article  PubMed  Google Scholar 

  59. Ozgu-Erdinc AS, Togrul C, Aktulay A, Buyukkagnici U, Yapar Eyi EG, Erkaya S. Factor XII (Hageman) levels in women with recurrent pregnancy loss. J Pregnancy. 2014;2014:459192.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bork K. A decade of change: recent developments in pharmacotherapy of hereditary angioedema (HAE). Clin Rev Allergy Immunol. 2016;51(2):183–92.

    Article  CAS  PubMed  Google Scholar 

  61. Gonzalez-Quevedo T, Larco JI, Marcos C, Guilarte M, Baeza ML, Cimbollek S, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2016;26(3):161–7.

    Article  CAS  PubMed  Google Scholar 

  62. Fox J, Vegh AB, Martinez-Saguer I, Wuillemin WA, Edelman J, Williams-Herman D, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc. 2017;38(3):216–21.

    Article  PubMed  Google Scholar 

  63. Bouillet L, Boccon-Gibod I, Gompel A, Floccard B, Martin L, Blanchard-Delaunay C, et al. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert((R))) in a French cohort. Eur J Dermatol. 2017;27(2):155–9.

    PubMed  Google Scholar 

  64. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy. 2012;32(10):902–9.

    Article  PubMed  Google Scholar 

  65. Schurmann D, Herzog E, Raquet E, Nolte MW, May F, Muller-Cohrs J, et al. C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk. Thromb Haemost. 2014;112(5):960–71.

    PubMed  PubMed Central  Google Scholar 

  66. Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc. 2013;34(6):519–22.

    Article  PubMed  Google Scholar 

  67. Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014;35(6):444–53.

    Article  CAS  PubMed  Google Scholar 

  68. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015;70(5):506–13.

    Article  CAS  PubMed  Google Scholar 

  69. Busse P, Bygum A, Edelman J, Lumry W, Machnig T, Martinez-Saguer I, et al. Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry. J Allergy Clin Immunol Pract. 2015;3(2):213–9.

    Article  PubMed  Google Scholar 

  70. Farkas H, Kohalmi KV, Veszeli N, Zotter Z, Varnai K, Varga L. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc. 2016;37(2):164–70.

    Article  CAS  PubMed  Google Scholar 

  71. Martinez Saguer I, Escuriola Ettingshausen C. Successful management of hereditary angioedema during pregnancy in a patient with heterozygous MTHFR mutation. Ann Allergy Asthma Immunol. 2017;118(6):734–5.

    Article  PubMed  Google Scholar 

  72. Farkas H, Kohalmi KV, Veszeli N, Toth F, Varga L. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res. 2016;42(8):1026–8.

    Article  PubMed  Google Scholar 

  73. Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence). 2017;8(3):178–81.

    Article  Google Scholar 

  74. Valdes G, Schneider D, Corthorn J, Ortiz R, Acuna S, Padilla O. Administration of angiotensin II and a bradykinin B2 receptor blocker in midpregnancy impairs gestational outcome in guinea pigs. Reprod Biol Endocrinol. 2014;12:49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Duck SC, Katayama KP. Danazol may cause female pseudohermaphroditism. Fertil Steril. 1981;35(2):230–1.

    Article  CAS  PubMed  Google Scholar 

  76. Reschini E, Giustina G, D’Alberton A, Candiani GB. Female pseudohermaphroditism due to maternal androgen administration: 25-year follow-up. Lancet. 1985;1(8439):1226.

    Article  CAS  PubMed  Google Scholar 

  77. Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology. 2004;145(2):790–8.

    Article  CAS  PubMed  Google Scholar 

  78. Picone O, Donnadieu AC, Brivet FG, Boyer-Neumann C, Fremeaux-Bacchi V, Frydman R. Obstetrical complications and outcome in two families with hereditary angioedema due to mutation in the F12 gene. Obstet Gynecol Int. 2010;2010:957507.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Garcia JFB, Takejima P, Veronez CL, Aun MV, Motta AA, Kalil J, et al. Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. J Allergy Clin Immunol Pract. 2018;6:1406–8.

    Article  PubMed  Google Scholar 

  80. Zuraw BL, Curd JG. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest. 1986;78:567–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol. 2007;156(5):1063–5.

    Article  CAS  PubMed  Google Scholar 

  82. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35:184–7.

    Article  CAS  PubMed  Google Scholar 

  83. Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res. 1979;13(9):1043–6.

    Article  CAS  PubMed  Google Scholar 

  84. Vermeesch JR, Voet T, Devriendt K. Prenatal and pre-implantation genetic diagnosis. Nat Rev Genet. 2016;17(10):643–56.

    Article  CAS  PubMed  Google Scholar 

  85. Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update. Allergy. 2018;73:1575–96.

    Article  CAS  PubMed  Google Scholar 

  86. Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand. 1970;49:241–2.

    Article  CAS  PubMed  Google Scholar 

  87. Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl. 1982;5:214–20.

    Article  CAS  PubMed  Google Scholar 

  88. Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand. 2009;88:1095–100.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of California San Diego, La Jolla, CA, USA

    Bruce L. Zuraw & Sandra C. Christiansen

  2. San Diego VA Healthcare, La Jolla, CA, USA

    Bruce L. Zuraw

Authors
  1. Bruce L. Zuraw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra C. Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce L. Zuraw .

Editor information

Editors and Affiliations

  1. Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, CA, USA

    Jennifer A. Namazy

  2. Department of Allergy, Kaiser Permanente Medical Center, San Diego, CA, USA

    Michael Schatz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zuraw, B.L., Christiansen, S.C. (2019). Hereditary Angioedema. In: Namazy, J., Schatz, M. (eds) Asthma, Allergic and Immunologic Diseases During Pregnancy. Springer, Cham. https://doi.org/10.1007/978-3-030-03395-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03395-8_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03394-1

  • Online ISBN: 978-3-030-03395-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation